ABSTRACT ATP-sensitive K ϩ (K ATP ) channels are present on the sarcolemma (sarcK ATP channels) and mitochondria (mitoK ATP channels) of cardiac myocytes. Amiodarone, a class III antiarrhythmic drug, reduces sudden cardiac death in patients with organic heart disease. The objective of the present study was to investigate the effects of amiodarone on sarcK ATP and mitoK ATP channels. Single sarcK ATP channel current and flavoprotein fluorescence were measured in guinea pig ventricular myocytes to assay sarcK ATP and mitoK ATP channel activity, respectively. Amiodarone inhibited the sarcK ATP channel currents in a concentration-dependent manner without affecting its unitary amplitude. The IC 50 values were 0.35 M in the inside-out patch exposed to an ATP-free solution and 2.8 M in the cell-attached patch under metabolic inhibition, respectively. Amiodarone (10 M) alone did not oxidize the flavoprotein. In addition, the oxidative effect of the mitoK ATP channel opener diazoxide (100 M) was unaffected by amiodarone. Exposure to ouabain (1 mM) for 30 min produced mitochondrial Ca 2ϩ overload, and the intensity of rhod-2 fluorescence increased to 246 Ϯ 16% of baseline (n ϭ 9). Amiodarone did not alter the ouabain-induced mitochondrial Ca 2ϩ overload (236 Ϯ 10% of baseline, n ϭ 7). Treatment with diazoxide significantly reduced the ouabain-induced mitochondrial Ca 2ϩ overload (158 Ϯ 15% of baseline, n ϭ 8, p Ͻ 0.05 versus ouabain); this effect was not abolished by amiodarone (154 Ϯ 10% of baseline, n ϭ 8, p Ͻ 0.05 versus ouabain). These results suggest that amiodarone inhibits sarcK ATP but not mitoK ATP channels in cardiac myocytes. Such an action of amiodarone may effectively prevent ischemic arrhythmias without causing ischemic damage.
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From the Cardiac Arrhythmia Suppression Trial (CAST) (The CAST Investigators, 1989) , strategies for the treatment of life-threatening ventricular tachyarrhythmias have changed markedly. Pure class III antiarrhythmic drugs such as d-sotalol and dofetilide have been developed as an alternative drug therapy to reduce sudden cardiac death (Singh et al., 1993) . However, a large-scale clinical trial with d-sotalol in patients after myocardial infarction has indicated disappointing results that the overall mortality of the drug-treated patients was higher than that of the placebo group (Waldo et al., 1996) . Amiodarone has been referred to as the prototype of class III antiarrhythmic drugs (Singh, 1983) , although profile of electropharmacological effects of the drugs is undoubtedly complex (for review, see Kodama et al., 1997) . Interestingly, amiodarone has been shown to prevent sudden cardiac death in patients with organic heart diseases, potentially by its antifibrillatory activity (Burkart et al., 1990; Cairns et al., 1997; Julian et al., 1997) . However, the underlying mechanism(s) of the favorable effect of amiodarone in such clinical trials is not well understood.
In cardiac myocytes, amiodarone has been shown to block two voltage-gated K ϩ channels, i.e., the delayed rectifier K ϩ channel and the inward rectifier K ϩ channel (Balser et al., 1991; Sato et al., 1994) . Moreover, previous studies in our laboratory have shown that amiodarone inhibits the ligandgated K ϩ channels, i.e., acetylcholine-sensitive muscarinic K ϩ channel and the Na ϩ -activated K ϩ channel (Mori et al., 1996; Watanabe et al., 1996) . So far, however, we have only limited knowledge about the effect of amiodarone on ATPsensitive K ϩ (K ATP ) channel, a ligand-gated K ϩ channel. K ATP channel is unique among K ϩ channels in being inhibited by cytoplasmic adenine nucleotides and thereby coupling metabolic events to cellular excitability (Noma, 1983) . Recent studies have suggested that cardiac myocytes contain K ATP channels not only in sarcolemmal plasma membrane (sarcK ATP channels) but also in mitochondrial inner membrane (mitoK ATP channels) (Garlid et al., 1996; Liu et al., 1998) . It is acknowledged that the K ATP channel is a hetero- octamer comprising two subunits: a pore-forming inwardly rectifying K ϩ channel subunit (Kir6.x) and a regulatory sulfonylurea receptor subunit (SURx) (for review, see Seino, 1999) . From the analyses of Kir6.1-and Kir6.2-deficient mice we have recently provided direct evidence that Kir6.2 form the pore region of cardiac sarcK ATP channels, whereas the molecular identity of mitoK ATP channels has not been established (Suzuki et al., 2001 Miki et al., 2002) . Although the relative roles of the sarcK ATP and mitoK ATP channels remain elusive, it has been suggested that openings of the sarcK ATP channels are arrhythmogenic (for review, see Wilde and Janse, 1994) , whereas openings of the mitoK ATP channels are cardioprotective (for review, see . In this regard, inhibition of sarcK ATP channel may prevent the ischemia-induced shortening of refractory period. In fact, the selective sarcK ATP channel blocker HMR 1883 has been shown to prevent ischemia-induced ventricular fibrillation (Billman et al., 1998; Wirth et al., 1999) . On the other hand, inhibition of mitoK ATP channels may produce significant damage to the ischemic myocardium. Several recent studies have demonstrated that the mitoK ATP channel blocker 5-hydroxydecanoate (5HD) abolishes the endogenous cardioprotective mechanism known as "ischemic preconditioning" (for review, see .
In terms of effects of amiodarone on sarcK ATP channel, Haworth et al. (1989) have demonstrated that amiodarone inhibits the rate of 86 Rb uptake, an index of sarcK ATP channel activity. A recent electrophysiological study by Holmes et al. (2000) has shown that amiodarone inhibits the sarcK ATP channel activity in rat ventricular myocytes. However, it still remains unclear whether amiodarone modulates the cardiac mitoK ATP channel activity. Accordingly, the present study examined the effects of amiodarone on sarcK ATP and mitoK ATP channels in guinea pig ventricular myocytes. The results presented here show that amiodarone inhibits sarcK ATP but not mitoK ATP channels in cardiomyocytes.
Materials and Methods
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication 85-23, revised 1985) .
Cell Preparation. Single ventricular myocytes of the guinea pig hearts were obtained by enzymatic dissociation, as described previously (Tohse et al., 1992) . The cells used in the present experiments had a regular shape with clear cross-striation.
Single SarcK ATP Channel Recording. Single sarcK ATP channel current recordings were performed by the inside-out and the cellattached configurations of the patch-clamp techniques. Single myocytes were superfused with the HEPES-buffered Tyrode's solution containing 143 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.33 mM NaH 2 PO 4 , 0.5 mM MgCl 2 , 5.5 mM glucose, and 5 mM HEPES (pH adjusted to 7.4 with NaOH). Patch electrodes were fabricated from glass capillaries (o.d. 1.5 mm) by a two-stage puller (PB-7; Narishige, Tokyo, Japan), and their tips coated with silicone and heat-polished. For inside-out patch recording, the internal solution contained 150 mM KCl, 1 mM EGTA, 5 mM HEPES, and 0.001 mM Na 2 -ATP (pH adjusted to 7.4 with KOH) and the external (pipette) solution contained 150 mM KCl, 2 mM CaCl 2 , and 5 mM HEPES (pH adjusted to 7.4 with KOH). For cell-attached patch recording, the same pipette solution was used. After the gigaohm seal between the patch electrode and the cell membrane was formed, cells were exposed to a glucose-free HEPES-buffered Tyrode's solution containing 0.2 mM 2,4-dinitrophenol (DNP), an uncoupler of oxidative phosphorylation.
When the openings of sarcK ATP channels occurred, various concentrations of amiodarone were added to the solution. These experiments were performed at room temperature (Ϸ22°C).
The single-channel currents were recorded by a patch-clamp amplifier (CEZ-2300; Nihon Kohden, Tokyo, Japan) and stored on videotapes through a pulse code modulator (VR-10B; InstruTECH Corporation, Port Washington, NY) for later analysis. The frequency response of the recording system was flat up to 37 kHz. The data were filtered at 2 kHz with a digital Gaussian filter and digitized at 10 kHz for data analysis with pClamp software (Axon Instruments, Union City, CA). Channel openings were identified by algorithm that used both amplitude and slope information, and measured with an interactive threshold for detecting events that was set at 50% of the expected amplitude. The probability of opening (Po) was calculated according to the following algorithm:
where n is the number of simultaneously active channels, t n is the length of time the channel is in state n, T is the total time of the recording, and N is the maximum number of channels detected during the experiment. Relative channel activities in the presence of varying concentration of amiodarone (NP/NPc) were fitted to the Hill equation with a Marquardt-Levenberg algorithm:
where [amiodarone] is the concentration of amiodarone, IC 50 is the half-maximum concentration for inhibition of amiodarone, and h is the Hill coefficient. Control channel currents were evaluated as an average of those from records before and after application of the drug because, in inside-out patches, the currents were gradually decreased and, in cell-attached patches, were gradually increased. The single-channel currents that did not recover after application of the drug were omitted from the data analysis to avoid contamination of the run-down of sarcK ATP channels. Flavoprotein Fluorescence Measurement. To stabilize the mitochondrial redox state, the cells were suspended in Dulbecco's modified Eagle's medium containing 10% fetal calf serum at room temperature until use. To index mitoK ATP channel activity, flavoprotein fluorescence was measured by a modification of method described by Sato et al. (1998) . Briefly, the cells were superfused with bath solution containing 143 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.33 mM NaH 2 PO 4 , 0.5 mM MgCl 2 , and 5 mM HEPES, adjusted to pH 7.4 with NaOH. Flavoprotein fluorescence was excited at 480 nm (for 200 ms every 10 s) and emitted at 520 nm. At the end of each experiment, cells were exposed to the mitochondrial uncoupler DNP (100 M) to obtain maximal flavoprotein oxidation. These experiments were performed at room temperature (Ϸ22°C). Emitted fluorescence was monitored with a cooled charge-coupled device digital camera (C4742-95; Hamamatsu Photonics, Hamamatsu, Japan). The imaging of flavoprotein was analyzed for average pixel intensities of regions of interest drawn to include whole cell and expressed as a percentage of the DNP-induced maximal oxidation, using an Aquacosmos image-processing system (Hamamatsu Photonics).
Mitochondrial Ca 2؉ Concentration ([Ca 2؉ ] m ) Measurement. The Ca 2ϩ fluorophore rhod-2 was used to measure changes of [Ca 2ϩ ] m . For rhod-2 loading, cells were plated on uncoated 35-mm Falcon culture dishes with a medium based on a 1:1 mixture of Dulbecco's modified Eagle's medium and HEPES-buffered Tyrode's solution, supplemented with 10% fetal calf serum. Then, cells were loaded with rhod-2 acetoxymethyl ester (10 M) for 120 min at 4°C. After cold loading, cells were incubated for 30 min at 37°C. This two-step cold loading/warm incubation protocol achieves exclusive loading of rhod-2 into the mitochondria (Trollinger et al., 2000) . Cells loaded with rhod-2 were perfused with a HEPES-buffered Tyrode's solution containing 2.7 mM CaCl 2 at 37°C. Rhod-2 fluorescence was excited at 540 nm (for 100 ms), with emission monitored through a 605-nm (55-nm bandpass) barrier filter. The imaging of rhod-2 was analyzed for average pixel intensities of regions of interest drawn to include whole cell, after correction for background, using an Aquacosmos image-processing system (Hamamatsu Photonics).
Chemicals. Amiodarone was a kind gift from Taisho Pharmaceutical (Omiya, Japan). Diazoxide, 5HD, glibenclamide, and ouabain were purchased from Sigma-Aldrich (St. Louis, MO). DNP was purchased from Wako Pure Chemicals (Osaka, Japan). Rhod-2 acetoxymethyl ester was purchased from Molecular Probes (Eugene, OR). For electrophysiological experiments, amiodarone was dissolved in absolute ethanol at a concentration of 10 mM and then added to the bath solution containing bovine serum albumin (0.03-1.0%), as described by Honjo et al. (1991) . Because bovine serum albumin alone enhanced the emitted fluorescence nonspecifically, stock solution of amiodarone was directly diluted in the perfusate for measurements of flavoprotein fluorescence. It was confirmed that the solvent of amiodarone affected neither the sarcK ATP channel current nor the flavoprotein fluorescence. Glibenclamide was dissolved in dimethyl sulfoxide at a concentration of 100 mM. Ouabain, 5HD, and DNP were dissolved in the perfusate.
Data Analysis. Data are presented as mean Ϯ S.E.M., and the number of cells or experiments is shown as n. Curve fits were performed with Origin 7J software (MicroCal Software, Northampton, MA). Intergroup comparisons are made by Student's t test for two groups and by analysis of variance followed by Fisher's post hoc test for multiple groups. A value of p Ͻ 0.05 was regarded as significant.
Results

Effect of Amiodarone on SarcK ATP Channel Current.
Effects of amiodarone on the sarcK ATP channel activity induced by metabolic blockade were evaluated in guinea pig ventricular cells. Figure 1A shows a representative sarcK ATP channel current recorded in the cell-attached mode from a cell exposed to DNP (0.2 mM)-containing, glucose-free solution. At the pipette potential of 0 mV, unitary currents through the inward rectifier K ϩ channel could be recorded using a K ϩ -rich (150 mM) pipette solution, which was identified from its smaller slope conductance and longer open time. After the commencement of the superfusion of the cell with the ischemia-simulating Tyrode's solution, opening the inward rectifier K ϩ channel decreased gradually, and singlechannel currents having larger unitary amplitude occurred. The latter channel was identified as sarcK ATP channel because the linear slope conductance obtained from the current-voltage relationship was 79.4 Ϯ 1.0 pS (n ϭ 3) and the channel opening was readily inhibited by the application of 1 to 10 M glibenclamide. During the continuous recording of the sarcK ATP channel activity, amiodarone was applied extracellularly. As shown in Fig. 1A , amiodarone effectively inhibited the channel openings. Amiodarone at a concentration of 10 M significantly decreased Po by 84 Ϯ 4% (from 0.25 Ϯ 0.04 to 0.05 Ϯ 0.03, n ϭ 8, p Ͻ 0.05) without affecting the amplitude of unitary events. Figure 1B illustrates the effect of amiodarone on the single sarcK ATP channel current recorded form an inside-out patch of ventricular cell. A single channel current was recorded at a holding potential of Ϫ40 mV with an internal solution containing 1 M ATP. The slope conductance of the unitary current from the current voltage relationship was 82 Ϯ 2 pS (n ϭ 3), and the current was reversibly inhibited by the application of 1 mM ATP to the internal solution, implying that the unitary current flowed through sarcK ATP channels. As shown in Fig. 1B , amiodarone at a concentration of 1 M significantly decreased Po by 79 Ϯ 9% (from 0.37 Ϯ 0.04 to 0.10 Ϯ 0.05, n ϭ 9, p Ͻ 0.05) without affecting the amplitude of unitary current. The sarcK ATP channel slowly reverted toward the control on changing to drug-free solution.
Amiodarone-induced changes in relative open probability (NP/NPc) of the inward sarcK ATP channel current recorded in the inside-out patch and in the cell-attached mode are summarized in Fig. 2 . Amiodarone inhibited the sarcK ATP channel current in a concentration-dependent manner, and the IC 50 values were 0.35 and 2.8 M in the inside-out patch and jpet.aspetjournals.org in the cell-attached mode, respectively. Furthermore, amiodarone (1 M) inhibited the outward component of the sarcK ATP channel current at a holding potential of ϩ40 mV in the inside-out patch membrane and decreased Po of the outward sarcK ATP channel current from 0.41 to 0.14 in two experiments.
Effect of Amiodarone on Flavoprotein Fluorescence. The effects of amiodarone on mitoK ATP channels were evaluated indirectly by measuring flavoprotein fluorescence. Figure 3, A and B, show the time course of flavoprotein fluorescence in a cell exposed to diazoxide and/or amiodarone. Diazoxide (100 M), a mitoK ATP channel opener, reversibly oxidized flavoprotein (Fig. 3A) . Exposure to amiodarone (10 M) alone had no effects on flavoprotein fluorescence. Subsequent application of diazoxide (100 M), in the continued presence of amiodarone, reversibly oxidized flavoprotein (Fig. 3B) . As summarized in Fig. 3C , diazoxide (100 M) alone increased flavoprotein oxidation to 32.4 Ϯ 3.1% of the DNP value (n ϭ 8). Amiodarone (10 M) did not oxidize the flavoprotein (4.8 Ϯ 1.8% of the DNP value, n ϭ 7). In the presence of amiodarone, diazoxide increased flavoprotein oxidation to 35.0 Ϯ 4.6% of the DNP value (n ϭ 7). This degree of oxidation was comparable to that observed in the absence of amiodarone. The results indicate that amiodarone does not affect mitoK ATP channel function.
Effect of Amiodarone on Mitochondrial Ca 2؉ Overload. We previously reported that the opening of mitoK ATP channels by diazoxide attenuates the mitochondrial Ca 2ϩ overload in rat ventricular myocytes (Ishida et al., 2001) . We therefore examined the effect of amiodarone on mitochondrial Ca 2ϩ overload. As summarized in Fig. 4 , treatment of myocytes with ouabain (1 mM) evoked the elevation of [Ca 2ϩ ] m , and the intensity of rhod-2 fluorescence after 30 min significantly increased to 249.5 Ϯ 16.2% of baseline (n ϭ 9, p Ͻ 0.001). Diazoxide (100 M) significantly attenuated the elevation of [Ca 2ϩ ] m during exposure to ouabain (157.8 Ϯ 15.5% of baseline, n ϭ 8, p Ͻ 0.05 versus ouabain), and the effect was antagonized by the mitoK ATP channel blocker 5HD (500 M, 258.1 Ϯ 28.1% of baseline, n ϭ 8). Amiodarone (10 M) alone did not increase the [Ca 2ϩ ] m (104.3 Ϯ 1.1% of baseline, n ϭ 8). Amiodarone per se did not attenuate the ouabain-induced increase in [Ca 2ϩ ] m (236.5 Ϯ 10.4% of baseline, n ϭ 7). Furthermore, even in the presence of amiodarone, diazoxide could attenuate the elevation of [Ca 2ϩ ] m during exposure to ouabain. These results indicate that amiodarone did not affect the mitoK ATP channel function.
Discussion
The first report of the effects of amiodarone on sarcK ATP channel came from Haworth et al. (1989) where amiodarone inhibited the 86 Rb uptake stimulated by rotenone plus ptrifluoromethoxy-phenylhydrazone with IC 50 value of 19.1 M in rat heart cells. Because the 86 Rb uptake was potently inhibited by glibenclamide, they concluded that the stimulated 86 Rb uptake might reflect the sarcK ATP channel activity. A recent study by Holmes et al. (2000) has provided electrophysiological evidence that amiodarone inhibits the sarcK ATP channel activity in rat ventricular myocytes, with apparent IC 50 value of 0.14 to 2.3 M. In agreement with previous reports, our present experiments demonstrated that amiodarone inhibits the sarcK ATP channel current in a concentration-dependent manner without affecting the unitary current both in the inside-out patches exposed to an ATPdeficient solution and in the intact cells under metabolic inhibition. We further found that there was a difference in the potency of sarcK ATP channel blockade by amiodarone between these two experimental conditions. In the inside-out patches, the sarcK ATP channel current could be inhibited by lower concentrations of amiodarone (IC 50 ϭ 0.35 M). In contrast, higher concentrations of amiodarone (IC 50 ϭ 2.8 M) were needed to inhibit the sarcK ATP channel current recorded in the cell-attached mode under metabolic inhibition. One possible explanation for the difference of the potency may be that amiodarone could have easy access to the sarcK ATP channel in the inside-out membrane patch from the internal solution. In the experiments using the cell-attached mode recording, amiodarone had to diffuse across the cell membrane from the bath solution and then bind to the site of action, i.e., sarcK ATP channel. Therefore, higher concentration of amiodarone in the bath solution might be needed for the inhibition of the sarcK ATP channel activity recorded in the cell-attached mode. Another explanation may be that the sarcK ATP channel current activated by metabolic stress might be more resistant to amiodarone. It was demonstrated that sulfonylurea drugs such as glibenclamide and tolbutamide were no longer able to inhibit the opening of sarcK ATP channels during severe metabolic stress although the precise mechanism(s) have not been fully clarified (Venkatesh et al., 1991; Findlay, 1993) . The effective concentration to inhibit the sarcK ATP channel current in this study was similar to or less than those needed to inhibit the other channels (Balser et al., 1991; Sato et al., 1994; Mori et al., 1996; Watanabe et al., 1996) . Moreover, acute and chronic administrations of amiodarone result in the plasma level of 0.1 to 6.5 g/ml (Harris et al., 1983; Ikeda et al., 1984; Raeder et al., 1985) , which correspond to approximately 0.16 to 10 M. Therefore, the inhibitory effect of the drug on the sarcK ATP channel in ischemic myocardium would be expected in clinical settings, even with acute administration.
To determine whether amiodarone affects the mitoK ATP channel function, we measured flavoprotein fluorescence as an index of mitoK ATP channel activity (Liu et al., 1998) . This approach enabled us to assay the function of mitoK ATP channels in intact cells, obviating the need for isolation of mitochondria or functional reconstitution. Hanley et al. (2002) , however, reported that the mitoK ATP channel opener diazoxide could not increase flavoprotein fluorescence in guinea pig ventricular myocytes. This discrepancy may stem from the different experimental conditions. They used freshly isolated myocytes and measured flavoprotein fluorescence in the presence of glucose. In our experiments, to stabilize the mitochondrial redox state, the cells were kept in a culture medium until use. Because redox state of the FAD/FADH 2 is linked to that of mitochondrial NAD ϩ /NADH (Chance et al., 1972) , mitoK ATP channel-induced flavoprotein oxidation is detectable only if uncompensated by increased production of electron donor (such as NADH). For this reason, we used the glucose-free solution for measurement of flavoprotein fluorescence, and indeed, diazoxide oxidized flavoprotein in guinea pig ventricular myocytes (Fig. 3A) . Using this experimental protocol, in the present study, we were unable to detect any significant effect of amiodarone (10 M) on flavoprotein fluorescence, i.e., amiodarone alone did not oxidize the flavoprotein and the oxidative effect of diazoxide was unaffected by amiodarone (Fig. 3, B and C) . These results suggest that amiodarone has no effect on the mitoK ATP channel function. Further support for this notion comes from the observation that, unlike diazoxide, amiodarone could not prevent the mitochondrial Ca 2ϩ overload (Fig. 4) . The experimental model of ouabain-induced mitochondrial Ca 2ϩ overload was used in our earlier study, in which we showed that in rat cardiomyocytes the mitoK ATP channel opener diazoxide attenuated the mitochondrial Ca 2ϩ overload and such effect associated with the depolarization of mitochondrial membrane potential (Ishida et al., 2001 ). The present study confirms that diazoxide prevents the mitochondrial Ca 2ϩ overload in guinea pig ventricular myocytes. Furthermore, when amiodarone was tested at a higher concentration (10 M), which is sufficient to block the sarcK ATP channels, it did not abrogate the cytoprotective effects of diazoxide. These results together indicate that amiodarone does not inhibit the opening of mitoK ATP channels, although further study is needed to define the chronic effects of amiodarone on mitoK ATP channels.
The activation of sarcK ATP channels shortens action potential duration and refractoriness, which may result in reentrant ventricular arrhythmias. Therefore, sarcK ATP channel blockers ought to be effective in ischemic arrhythmias, by preventing the action potential shortening. This concept is supported by the facts that the selective sarcK ATP channel blocker HMR 1883 effectively prevented ischemia-induced ventricular fibrillation (Billman et al., 1998; Wirth et al., 1999) . Blockade of sarcK ATP channels may predispose to aggravate ischemic injury by increasing the Ca 2ϩ influx. Indeed, complete loss of sarcK ATP channel function in Kir6.2-deficient mice resulted in greater contractile dysfunction after ischemia/reperfusion . In rabbit hearts, however, HMR 1883 did not abolish the endogenous cardioprotective mechanism known as ischemic preconditioning (Jung et al., 2000) . Thus, there may be species differences with regard to relative importance of sarcK-ATP channels in cardioprotection. Alternatively, there is ample evidence suggesting that inhibition of mitoK ATP channel was detrimental to ischemic cardioprotection (O'Rourke, 2000) . In this respect, the lack of effect of amiodarone on mitoK ATP channel is of advantage in management of ischemic arrhythmias compared with nonselective K ATP channel blockers such as glibenclamide, because the drug may effectively prevent arrhythmias without aggravating tissue damage. Such a salutary effect of amiodarone on ischemic myocardium may in part explain the reduction of cardiac death in patients with myocardial infarction, observed in several clinical trials such as Canadian Amiodarone Myocardial Infarction Arrhythmia Trial and European Myocardial Infarct Amiodarone Trial (Cairns et al., 1997 , Julian et al., 1997 .
